The House Judiciary Committee cleared four bills seeking to curb brand name manufacturer practices that delay the entry of generic drugs. While the measures have been considered in previous congresses, they may have a better chance of getting through the House and Senate this year since they have bipartisan support. However, the votes during markup show they still face opposition.
During a session that began on 29 September and resumed the next morning, the committee voted by wide margins to...





